About this Journal Submit a Manuscript Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 985404, 5 pages
http://dx.doi.org/10.1155/2013/985404
Clinical Study

Growth Factors Serum Levels in Coronary Artery Disease Patients Scheduled for Bypass Surgery: Perioperative Dynamics and Comparisons with Healthy Volunteers

1North Estonia Medical Centre, Clinic of Anaesthesiology, Sütiste 19, 13419 Tallinn, Estonia
2Department of Anaesthesiology and Intensive Care, University of Tartu, Puusepa 1a, 50406 Tartu, Estonia
3Institute of Biochemistry, Centre of Excellence for Translational Medicine, University of Tartu, Ravila 19, 50411 Tartu, Estonia

Received 21 April 2013; Accepted 9 July 2013

Academic Editor: Kan Kajimoto

Copyright © 2013 Inga Karu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. T. Vuorio, S. Jauhiainen, and S. Ylä-Herttuala, “Pro- and anti-angiogenic therapy and atherosclerosis with special emphasis on vascular endothelial growth factors,” Expert Opinion on Biological Therapy, vol. 12, no. 1, pp. 79–92, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. P. B. J. Burton, V. J. Owen, S. Hafizi et al., “Vascular endothelial growth factor release following coronary artery bypass surgery: extracorporeal circulation versus “beating heart” surgery,” European Heart Journal, vol. 21, no. 20, pp. 1708–1713, 2000. View at Publisher · View at Google Scholar · View at Scopus
  3. J. Lorita, G. Camprecíos, M. Soley, and I. Ramírez, “ErbB receptors protect the perfused heart against injury induced by epinephrine combined with low-flow ischemia,” Growth Factors, vol. 27, no. 4, pp. 203–213, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. N. A. Neiken, S. R. Coughlin, D. Gordon, and J. N. Wilcox, “Monocyte chemoattractant protein-1 in human atheromatous plaques,” Journal of Clinical Investigation, vol. 88, no. 4, pp. 1121–1127, 1991. View at Scopus
  5. R. Deo, A. Khera, D. K. McGuire et al., “Association among plasma levels of monocyte chemoattractant protein-1, traditional cardiovascular risk factors, and subclinical atherosclerosis,” Journal of the American College of Cardiology, vol. 44, no. 9, pp. 1812–1818, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. R. C. Hoogeveen, A. Morrison, E. Boerwinkle et al., “Plasma MCP-1 level and risk for peripheral arterial disease and incident coronary heart disease: atherosclerosis Risk in Communities study,” Atherosclerosis, vol. 183, no. 2, pp. 301–307, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. C. Herder, J. Baumert, B. Thorand et al., “Chemokines and incident coronary heart disease: results from the MONICA/KORA Augsburg case-cohort study, 1984–2002,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 26, no. 9, pp. 2147–2152, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. R. Tamura, J.-I. Miyagawa, M. Nishida et al., “Immunohistochemical localization of Betacellulin, a member of epidermal growth factor family, in atherosclerotic plaques of human aorta,” Atherosclerosis, vol. 155, no. 2, pp. 413–423, 2001. View at Publisher · View at Google Scholar · View at Scopus
  9. J. Gosling, S. Slaymaker, L. Gu et al., “MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B,” Journal of Clinical Investigation, vol. 103, no. 6, pp. 773–778, 1999. View at Scopus
  10. B. Amasyalia, S. Kosea, H. Kursaklioglua, C. Barcina, and A. Kilicb, “Monocyte chemoattractant protein-1 in acute coronary syndromes: complex vicious interaction,” International Journal of Cardiology, vol. 136, pp. 356–357, 2009.
  11. C. Morgan, M. Zappitelli, and P. Gill, “Statin prophylaxis and inflammatory mediators following cardiopulmonary bypass: a systematic review,” Critical Care, vol. 13, no. 5, article R165, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. K. Nakamura, H. Masuda, H. Kariyazono et al., “Effects of atorvastatin and aspirin combined therapy on inflammatory responses in patients undergoing coronary artery bypass grafting,” Cytokine, vol. 36, no. 5-6, pp. 201–210, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. P. Libby, “Current concepts of the pathogenesis of the acute coronary syndromes,” Circulation, vol. 104, no. 3, pp. 365–372, 2001. View at Scopus
  14. A. Yadav, V. Saini, and S. Arora, “MCP-1: chemoattractant with a role beyond immunity: a review,” Clinica Chimica Acta, vol. 411, no. 21-22, pp. 1570–1579, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Castellheim, T. N. Hoel, V. Videm et al., “Biomarker profile in off-pump and on-pump coronary artery bypass grafting surgery in low-risk patients,” Annals of Thoracic Surgery, vol. 85, no. 6, pp. 1994–2002, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. F. Onorati, A. S. Rubino, S. Nucera et al., “Off-pump coronary artery bypass surgery versus standard linear or pulsatile cardiopulmonary bypass: endothelial activation and inflammatory response,” European Journal of Cardio-Thoracic Surgery, vol. 37, no. 4, pp. 897–904, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. Y. Kusumanto, R. Tio, B. Loef, W. Sluiter, N. Mulder, and G. Hospers, “Systemic VEGF levels after coronary artery bypass graft surgery reflects the extent of inflammatory response,” Acute Cardiac Care, vol. 8, no. 1, pp. 41–45, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. E. Melgarejo, M. Á. Medina, F. Sánchez-Jiménez, and J. L. Urdiales, “Monocyte chemoattractant protein-1: a key mediator in inflammatory processes,” International Journal of Biochemistry and Cell Biology, vol. 41, no. 5, pp. 998–1001, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. N. Sarwar and A. S. Butterworth, “Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies,” The Lancet, vol. 379, no. 9822, pp. 1205–1213, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. A. G. Giurgea, C. Margeta, T. Maca et al., “Simvastatin reduces serum level of vascular endothelial growth factor in hypercholesterolemic patients,” Journal of Cardiovascular Pharmacology, vol. 47, no. 1, pp. 30–36, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. H. Berrahmoune, J. V. Lamont, B. Herbeth, P. S. FitzGerald, and S. Visvikis-Siest, “Biological determinants of and reference values for plasma interleukin-8, monocyte chemoattractant protein-I, epidermal growth factor, and vascular endothelial growth factor: results from the STANISLAS cohort,” Clinical Chemistry, vol. 52, no. 3, pp. 504–510, 2006. View at Publisher · View at Google Scholar · View at Scopus